Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.47 |
| ▸ | CTSV | O60911 | 9/20 | 0.47 |
| ▸ | CTSB | P07858 | 9/20 | 0.47 |
| ▸ | CTSS | P25774 | 9/20 | 0.47 |
| ▸ | CTSL | P07711 | 6/20 | 0.42 |
| ▸ | DDX3X | O00571 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404166 | 1.00 | CTSK (0.47) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6406171 | 1.00 | CTSK (0.47) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6401707 | 0.93 | CTSK (0.44) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6401711 | 0.93 | CTSK (0.44) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6407622 | 0.93 | CTSK (0.43) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6403132 | 0.93 | CTSK (0.43) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6403135 | 0.93 | CTSK (0.43) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6404533 | 0.93 | CTSK (0.46) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6404535 | 0.93 | CTSK (0.46) | CTSKCTSVCTSBCTSSCTSL | |
| SCHEMBL6408243 | 0.93 | CTSK (0.46) | CTSKCTSVCTSBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSV 10/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.